RGEN

#1067
Repligen Corp
131.0300 USD
+6.88%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
131.0300
131.0300
Rango anual
109.6600
175.5700
Cambio diario
+6.88%
Variación mensual
+13.62%
Variación en los últimos 6 meses
-20.92%
Cambio anual
-20.92%
Cierres anteriores
122.5900
Abrir
131.0300
Bid
Ask
Mínimo
131.0300
High
131.0300
Volumen
71
Ver el calendario completo

Financials

Visión general Informes Estadísticas
Trimestre Año
  • Market Capitalization 7.3811 B
  • Employee 2 000
  • Founded 1981
  • CEO Tony J. Hunt
  • Website www.repligen.com
  • Headquarter Delaware, United States
  • FIGI BBG000BS48J3
  • Industry Technology
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
190.53
Relación precio/flujo de caja
0.01

Repligen Corporation

Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. The company is based in Waltham, Massachusetts, and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biopharmaceutical drug developers and contract development and manufacturing organizations worldwide.

Noticias